Medicine prices are facing increasing pricing pressure—and early 2026 is one of the first notable periods where the list ...
Over the past four decades, rare disease drug development has evolved from a scientific aspiration into a central pillar of biopharmaceutical innovation. Regulatory reforms, scientific breakthroughs, ...
HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused healthcare accelerator that facilitates guaranteed hospital pilot projects and clinical trials for ...
The Institute for Clinical and Economic Review (ICER) has published its annual report on "unsupported" price increases for medicines that it says have added around $815 million to US drug spending.
With the US remaining the dominant global market for the pharma industry, pharmaphorum spoke with John Castellani, CEO of the public policy group The Pharmaceutical Research and Manufacturers of ...
If you earn more than $109,000 ($218,000 if you're married), you pay higher monthly rates for both Medicare Part B (doctor visits) and D (prescription drugs). For 2026, your costs for Medicare Parts B ...
Patients in the US currently benefit from faster access 1 to more innovations 2 compared with their ex-US peers. American patients consistently report valuing access to pharmaceuticals and the ...
Medicare tax is taken out of your paycheck to pay for Medicare Part A, which provides hospital insurance to seniors and people with disabilities. The total Medicare tax amount is split between ...
It is critical to understand assessment and appraisal processes by HTAs and that important differences may arise as part of those processes across countries. The complexity of HTA processes and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results